Ignacio Melero

2025

1. 4-1BB agonist targeted to fibroblast activation protein α synergizes with radiotherapy to treat murine breast tumor models

   Journal for immunotherapy of cancer, Vol. 13, Núm. 2

2. A Phase I Dose Escalation and Cohort Expansion Study of CB307, a Trispecific Humabody against PSMA, CD137, and Albumin in Patients with PSMA-Positive Solid Tumors

   Clinical Cancer Research, Vol. 31, Núm. 16, pp. 3388-3399

3. A Phase II Study of Perioperative Avelumab plus Chemotherapy for Patients with Resectable Gastric Cancer or Gastroesophageal Junction Cancer – The MONEO Study

   Clinical Cancer Research, Vol. 31, Núm. 14, pp. 2890-2898

4. Antigen-presenting mast cells are new players in breast cancer immunotherapy

   Nature Medicine

5. Association of PD-1, LAG-3 and TIM-3 expression on intratumoral CD8 T-cells with response to atezolizumab in a Real-World-Evidence biomarker study for advanced urothelial carcinoma patients

   OncoImmunology, Vol. 14, Núm. 1

6. Author Correction: Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy (Nature, (2019), 569, 7756, (428-432), 10.1038/s41586-019-1162-y)

   Nature

7. Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial

   Nature Medicine, Vol. 31, Núm. 1, pp. 152-164

8. BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203

   Journal of Clinical Oncology, Vol. 43, Núm. 25, pp. 2806-2815

9. Barriers to publishing early phase clinical trials: the oncologists’ perspective

   Oncologist, Vol. 30, Núm. 4

10. Correction to: Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours (Nature, (2025), 637, 8048, (1218-1227), 10.1038/s41586-024-08305-z)

    Nature

11. Cross-priming in cancer immunology and immunotherapy

    Nature Reviews Cancer, Vol. 25, Núm. 4, pp. 249-273

12. Dual ENPP1/ATM depletion blunts DNA damage repair boosting radioimmune efficacy to abrogate triple-negative breast cancer

    Signal Transduction and Targeted Therapy, Vol. 10, Núm. 1

13. Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020

    Journal for ImmunoTherapy of Cancer, Vol. 13, Núm. 2

14. Erratum: BO-112 Plus Pembrolizumab for Patients With Anti–PD-1–Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203 (Journal of Clinical Oncology (2025) DOI: 10.1200/JCO-24-02595)

    Journal of Clinical Oncology

15. Immunocytokines and cytokine neutralization for cancer immunotherapy

    Trends in Cancer, Vol. 11, Núm. 8, pp. 790-805

16. Immunotherapy with conventional type-1 dendritic cells induces immune memory and limits tumor relapse

    Nature Communications , Vol. 16, Núm. 1

17. Intraperitoneal administration of mRNA encoding interleukin-12 for immunotherapy in peritoneal carcinomatosis

    Journal of Nanobiotechnology , Vol. 23, Núm. 1

18. Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours

    Nature, Vol. 637, Núm. 8048, pp. 1218-1227

19. Preclinical ex vivo and in vivo models to study immunotherapy agents and their combinations as predictive tools toward the clinic

    Journal for immunotherapy of cancer, Vol. 13, Núm. 10

20. Routing immunomodulatory cytokine-encoded mRNAs to the omentum: turning an enemy into an ally in peritoneal metastasis

    OncoImmunology